David J. Shealy - Concepedia

Author

David J. Shealy

Reaction Biology Corporation (United States)ORCID

Also Known As

D J Shealy, D Shealy, D. J. Shealy, D. Shealy, D.J. Shealy, DAVID J. SHEALY, David J Shealy, David J. Shealy, David Shealy, M. Rahman

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Reaction Biology Corporation (United States)University of Rochester Medical Center University of Rochester Columbia University Irving Medical Center Michigan Medicine

About

David J. Shealy is an author at Reaction Biology Corporation (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	3.7K
2	Allergy	4	4	1K
3	Natural Sciences	3	3	82
4	Health Sciences	1	1	36
5	Biochemistry	1	1	13

David J. Shealy

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus Eneida C. Villanueva, Srilakshmi Yalavarthi, Céline C. Berthier, The Journal of Immunology Innate Immune SystemImmunologyImmune RegulationPathologyInnate Immunity	2011	1.2K
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody David Knight, Han Trinh, Junming Le, Molecular Immunology Autoimmune DiseaseAllergyImmunologyImmunodominanceAntibody Screening	1993	710
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists Bernie Scallon, Ann Cai, Nancy Solowski, Journal of Pharmacology and Experimental Therapeutics	2002	667
Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis Filip J. Baert, Geert D’Haens, Marc Peeters, Gastroenterology InflammationChronic Inflammatory DiseasesTumor Necrosis FactorAnti-inflammatoryMucosal Immunology	1999	467
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease SE Plevy, C J Landers, John Prehn, The Journal of Immunology	1997	387
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. Tsunehiro Yasuda, Herman K. Gold, John T. Fallon, Journal of Clinical Investigation ImmunologyThrombosisHematologyPlatelet ConcentratesLeft Anterior Descending	1988	243
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α David J. Shealy, Ann Cai, Kim Staquet, mAbs ImmunologyImmune RegulationPathologyImmunologic MechanismImmunotherapeutics	2010	239
The Mouse/Human Chimeric Monoclonal Antibody cA2 Neutralizes TNF In Vitro and Protects Transgenic Mice from Cachexia and TNF Lethality In Vivo Scott A. Siegel, David J. Shealy, Marian T. Nakada, Cytokine Tnf LethalityHuman TnfImmunologyCell DeathPathology	1995	227
TNF-α drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice Li‐Chin Yao, Jennifer Feng, Talia Romano, Journal of Clinical Investigation	2009	204
Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease Freddy Cornillie, David J. Shealy, Geert D’Haens, Alimentary Pharmacology & Therapeutics	2001	200

Page 1